Harrow And 2 Other Growth Stocks Insiders Are Betting On
In the last week, the United States market has remained flat, although it is up 20% over the past year with earnings forecasted to grow by 17% annually. In such a promising environment, growth companies with high insider ownership can be particularly appealing as insiders' confidence in their own firms often signals potential for sustained expansion and value creation.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 34.3% | 69.4% |
| Upstart Holdings (UPST) | 13.9% | 66.5% |
| Precigen (PGEN) | 11.7% | 55.4% |
| Karman Holdings (KRMN) | 14.9% | 54% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 17.2% | 23% |
| Carlyle Group (CG) | 27.5% | 20.5% |
| Astera Labs (ALAB) | 10% | 33.2% |
| AppLovin (APP) | 23.3% | 20.6% |
| Almonty Industries (ALM) | 10.8% | 37.1% |
Let's take a closer look at a couple of our picks from the screened companies.
Harrow (HROW)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic products in the United States with a market cap of $1.48 billion.
Operations: The company's revenue is derived from two main segments: Branded products generating $212.51 million and Compounding products contributing $63.08 million.
Insider Ownership: 16.4%
Harrow demonstrates potential as a growth company with high insider ownership, supported by its strategic acquisitions and product expansions. Recent earnings showed increased revenue to US$70.66 million, though it reported a net loss of US$17.27 million for the quarter. The acquisition of TYRVAYA nasal spray enhances its dry eye portfolio and offers differentiation in treatment options. Analysts forecast substantial revenue growth at 28.2% annually, outpacing the broader market, with profitability expected within three years.
- Dive into the specifics of Harrow here with our thorough growth forecast report.
- In light of our recent valuation report, it seems possible that Harrow is trading behind its estimated value.
Hennessy Capital Investment VII (HVII)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Hennessy Capital Investment Corp. VII is a company without significant operations, with a market cap of $273.51 million.
Operations: Hennessy Capital Investment Corp. VII currently does not generate revenue from distinct segments, as it lacks significant operations.
Insider Ownership: 24.4%
Hennessy Capital Investment Corp. VII shows promise with significant forecasted earnings growth of 78.9% annually, outpacing the US market's 17%. Despite reporting a decline in net income for the second quarter to US$0.92 million from US$1.52 million a year ago, its projected revenue growth of 71.5% annually is expected to surpass market averages significantly. However, it currently generates less than US$1 million in revenue and has negative shareholders' equity, indicating potential financial challenges ahead.
- Click here to discover the nuances of Hennessy Capital Investment VII with our detailed analytical future growth report.
- According our valuation report, there's an indication that Hennessy Capital Investment VII's share price might be on the expensive side.
Alphatec Holdings (ATEC)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Alphatec Holdings, Inc. is a medical technology company that focuses on designing and developing technologies for the surgical treatment of spinal disorders, with a market cap of approximately $1.46 billion.
Operations: The company generates revenue primarily from its Medical Products segment, which totaled $815.05 million.
Insider Ownership: 10.2%
Alphatec Holdings is poised for strong growth, with earnings expected to increase 62.5% annually and profitability anticipated within three years, outperforming market averages. Despite a net loss of US$25.78 million in Q2 2026, this marks an improvement from the previous year's US$41.14 million loss. Insider ownership remains high with no substantial insider trading activity recently reported. The company reaffirmed its revenue guidance of US$882 million for 2026, indicating robust operational momentum despite slower revenue growth than the broader market.
- Delve into the full analysis future growth report here for a deeper understanding of Alphatec Holdings.
- Our valuation report here indicates Alphatec Holdings may be undervalued.
Taking Advantage
- Dive into all 183 of the Fast Growing US Companies With High Insider Ownership we have identified here.
- Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com